The 3C (Cell Culture, Computer Simulation, Clinical Trial) Solution for Optimizing the 3R (Replace, Reduction, Refine) Framework during Preclinical Research Involving Laboratory Animals
- 9 April 2025
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 8 (5) , 1188-1204
Abstract
Preclinical research has traditionally utilized laboratory animals to elucidate the safety, tolerability, pharmacokinetics, and pharmacodynamics of new chemical entities prior to human trials. The use of animal models has been pivotal in advancing scientific knowledge and medical breakthroughs, contributing significantly to our understanding of the complex biological processes and human diseases. However, many promising treatments that have demonstrated efficacy in animal studies have failed to translate to human subjects during clinical trials. Consequently, animal testing faces ethical concerns and criticism regarding its predictive reliability for human responses. This has led to the development of 3R principles (Replacement, Reduction, Refinement), introduced in 1959, advocating for alternative methods and improved animal welfare in research. Furthermore, regulatory frameworks and recent legislation, such as the 2022 FDA Modernisation Act, emphasize modern scientific alternatives to traditional animal testing. Emerging approaches, known as the 3Cs─cell culture, computer simulation, and phase 0 clinical trials─offer promising nonanimal solutions that could accelerate drug development and address ethical concerns, potentially rendering preclinical research more humane and efficient.Keywords
This publication has 172 references indexed in Scilit:
- How to improve R&D productivity: the pharmaceutical industry's grand challengeNature Reviews Drug Discovery, 2010
- The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trialsBritish Journal of Cancer, 2007
- Introduction to animal cell culture technology—past, present and futureCytotechnology, 2006
- Role of Caco-2 Cell Monolayers in Prediction of Intestinal Drug AbsorptionBiotechnology Progress, 2006
- Alternatives to animal experimentation: The regulatory backgroundToxicology and Applied Pharmacology, 2005
- Permeability profiles of M-alkoxysubstituted pyrrolidinoethylesters of phenylcarbamic acid across caco-2 monolayers and human skin.Pharmaceutical Research, 2002
- ICH Guidelines—Implementation of the 3Rs (Refinement, Reduction, and Replacement): Incorporating Best Scientific Practices into the Regulatory ProcessILAR Journal, 2002
- Approaches to developing alternative and predictive toxicology based on PBPK/PD and QSAR modeling.Environmental Health Perspectives, 1998
- Elixirs, Diluents, and the Passage of the 1938 Federal Food, Drug and Cosmetic ActAnnals of Internal Medicine, 1995
- Physiologically based pharmacokinetics and the risk assessment process for methylene chlorideToxicology and Applied Pharmacology, 1987